Analysts Set Oculis Holding AG (NASDAQ:OCS) PT at $38.33

Shares of Oculis Holding AG (NASDAQ:OCS) have been assigned an average recommendation of “Moderate Buy” from the ten research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $38.3333.

Several research firms recently commented on OCS. Guggenheim reduced their price target on shares of Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Wall Street Zen cut shares of Oculis from a “sell” rating to a “strong sell” rating in a research report on Sunday, July 12th. JPMorgan Chase & Co. dropped their target price on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Finally, Stifel Nicolaus decreased their price target on shares of Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, June 1st.

Oculis Stock Performance

Shares of Oculis stock opened at $12.07 on Thursday. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $12.72 and its two-hundred day moving average is $22.47. Oculis has a 52 week low of $10.52 and a 52 week high of $34.47. The company has a market capitalization of $699.82 million, a PE ratio of -5.67 and a beta of 0.51.

Oculis (NASDAQ:OCS) last released its earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%. As a group, analysts expect that Oculis will post -2.27 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Gildi lifeyrissjodur bought a new position in shares of Oculis during the 4th quarter worth $50,250,000. Perceptive Advisors LLC purchased a new position in shares of Oculis during the fourth quarter valued at $9,862,000. Aberdeen Group plc raised its holdings in shares of Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after acquiring an additional 493,827 shares in the last quarter. SR One Capital Management LP lifted its stake in Oculis by 98.8% in the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock worth $12,801,000 after acquiring an additional 318,522 shares during the period. Finally, Alyeska Investment Group L.P. grew its holdings in Oculis by 152.3% during the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock worth $6,617,000 after acquiring an additional 200,000 shares in the last quarter. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.